for life science researches
in the promotion of human health and welfare.
These accomplishments are then utilized in Korean customized medicine study and additional life science researches in the promotion of human health and welfare.
The company focuses on the development of anti-cancer drugs. MedPacto has two small molecules under the preclinical development for oncology therapeutics. One of them, TEW-7197, is an inhibitor of ALK-5 to block signal transduction by TGF-b and is the most advanced one in MedPacto’s development pipeline. TEW-7197 will be in clinical phase 1 on April, 2014. Another is TEW-0201 is an inhibitor of BRAF and c-RAF and showed an excellent efficacy in preclinical animal models. Read More →